The North America Diabetes Care Devices Market report segments the industry into Product (Monitoring Devices, Management Devices) and Geography (United States, Canada, Rest of North America). Get five years of historical data alongside five-year market forecasts.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

North America Diabetes Care Devices Market size was valued at USD 15.7 Billion in 2023 and is projected to reach USD 29.3 Billion by 2031 growing at a CAGR of 8.2% from 2024 to 2031.

Key Market Drivers:

Chronic Disease Prevalence: Extensive increase in diabetes prevalence across North American populations drives substantial demand for advanced diabetes care technologies.

Technological Innovation: Expanding medical technology sector and increasing investment in advanced diabetes care technologies drive demand for reliable, high-performance monitoring and treatment devices.

The North America Diabetes Care Devices report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

The global diabetes care devices market, valued at approximately $34.66 billion in 2025, is poised for significant growth driven by the rising prevalence of diabetes worldwide and advancements in device technology. The increasing geriatric population, coupled with lifestyle changes contributing to higher rates of type 2 diabetes, are key market drivers. Technological advancements, such as the development of continuous glucose monitoring (CGM) systems and insulin delivery devices with improved accuracy and convenience, are further fueling market expansion. While the market faces restraints like high device costs and the need for ongoing patient education, the ongoing development of minimally invasive and user-friendly technologies is mitigating these challenges. The market is segmented by application (medical care, personal care) and device type (blood glucose meters, test strips, insulin pumps, syringes, and others). Leading players, including Roche, Medtronic, J&J, Abbott, and others, are strategically investing in research and development, expanding their product portfolios, and pursuing strategic partnerships to enhance their market position. Regional analysis shows strong demand in North America and Europe, due to high diabetes prevalence and established healthcare infrastructure, but significant growth potential exists in Asia-Pacific regions as healthcare access improves. The forecast period (2025-2033) anticipates continued market expansion, propelled by innovative product launches and increasing healthcare expenditure. Specific CAGR data was not provided; however, given market dynamics, a conservative estimate would place the annual growth rate between 5-7% throughout the forecast period. The competitive landscape is marked by both large multinational corporations and specialized diabetes care device manufacturers. These companies are engaged in intense competition, focusing on innovation, product differentiation, and expansion into emerging markets. Future market growth will largely depend on factors such as technological advancements leading to more accurate, less invasive, and more user-friendly devices, and government initiatives to improve diabetes management and healthcare access, particularly in developing economies. The market’s success will depend on addressing challenges such as affordability and accessibility, along with ongoing education to ensure proper device usage and management of diabetes.

The report on North America Diabetes Care Devices & Drugs covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

The global diabetes care devices market, valued at $34.66 billion in 2025, is poised for substantial growth. While a precise CAGR isn't provided, considering the prevalence of diabetes globally and ongoing technological advancements in device development, a conservative estimate of 5-7% annual growth is reasonable over the forecast period (2025-2033). This growth is fueled by several key drivers: the rising incidence of diabetes worldwide, particularly type 2 diabetes; an aging global population increasing susceptibility to the disease; the growing adoption of continuous glucose monitoring (CGM) systems offering improved convenience and accuracy; and the increasing availability of advanced insulin delivery systems like insulin pumps and smart pens. Market segmentation reveals strong demand across various device types, including blood glucose meters, test strips, and insulin delivery systems. Geographic distribution reflects the highest market share in North America and Europe, driven by high diabetes prevalence rates and access to advanced healthcare infrastructure; however, significant growth potential exists in Asia-Pacific regions due to increasing awareness and rising disposable incomes. While challenges such as high device costs and inconsistent healthcare access in certain regions exist, technological advancements and greater affordability are expected to mitigate these restraints. The market is highly competitive, with key players like Roche, Medtronic, J&J, Abbott, and others constantly innovating to enhance device features and expand their market share. Strategic partnerships, mergers, and acquisitions are likely to further shape the market landscape. The forecast period (2025-2033) anticipates continuous market expansion, driven by improved diagnostic tools, advanced therapeutic solutions, and a rising focus on diabetes management. Specific growth within each device segment will depend on factors such as technological advancements, regulatory approvals, and pricing strategies. The long-term outlook for the diabetes care devices market remains overwhelmingly positive, fueled by unmet needs and consistent technological progress.

By 2035, the North America Diabetes Care Devices Market is estimated to expand to USD 35.75 Billion, showcasing a robust CAGR of 9.2% between 2025 and 2035, starting from a valuation of USD 13.58 Billion in 2024.

Diabetes Care Devices Market Outlook

According to our latest research, the global Diabetes Care Devices market size reached USD 32.7 billion in 2024, reflecting robust demand across both developed and emerging economies. The market is expected to expand at a steady CAGR of 7.1% from 2025 to 2033, with the overall market projected to reach USD 60.7 billion by 2033. The growth of this market is primarily driven by the rising global prevalence of diabetes, technological advancements in glucose monitoring and insulin delivery, and increasing awareness regarding diabetes management and patient self-care.

The most significant growth factor for the diabetes care devices market is the alarming rise in diabetes incidence worldwide. A sedentary lifestyle, increasing obesity rates, and aging populations are contributing to a surge in both Type 1 and Type 2 diabetes cases. As a result, the demand for advanced blood glucose monitoring devices, continuous glucose monitoring systems, and innovative insulin delivery solutions is escalating. Furthermore, governments and healthcare organizations are launching various awareness campaigns and screening programs, which are boosting early diagnosis and, consequently, the adoption of diabetes care devices. The integration of digital health technologies and smartphone applications with diabetes care devices is also enhancing patient engagement and adherence, further fueling market growth.

Technological advancements play a pivotal role in shaping the diabetes care devices market landscape. Continuous innovations in glucose monitoring, such as the advent of minimally invasive and non-invasive monitoring systems, have significantly improved patient comfort and compliance. The introduction of smart insulin pens, closed-loop insulin delivery systems, and wearable continuous glucose monitors has revolutionized diabetes management, enabling real-time monitoring and precise insulin dosing. These advancements not only enhance patient outcomes but also reduce the burden of complications associated with poorly managed diabetes. Moreover, the integration of artificial intelligence and data analytics in diabetes care devices is empowering patients and healthcare professionals with actionable insights, fostering personalized treatment approaches.

The expansion of home-based diabetes care and the growing emphasis on patient-centric healthcare are also major contributors to market growth. With the increasing preference for self-monitoring and at-home care, there is a rising demand for user-friendly and portable diabetes care devices. This trend is further supported by the proliferation of online pharmacies and e-commerce platforms, making these devices more accessible to a broader patient population. Additionally, favorable reimbursement policies and the growing availability of diabetes care devices in retail and hospital pharmacies are facilitating market penetration, especially in emerging economies. As the focus on preventive healthcare intensifies, the adoption of diabetes care devices is expected to witness sustained momentum throughout the forecast period.

Regionally, North America dominates the diabetes care devices market, accounting for the largest share in 2024, followed by Europe and the Asia Pacific. The high prevalence of diabetes, advanced healthcare infrastructure, and strong presence of leading market players contribute to North America's market leadership. Meanwhile, the Asia Pacific region is poised for the fastest growth, driven by a rapidly increasing diabetic population, improving healthcare access, and rising awareness about diabetes management. Latin America and the Middle East & Africa are also witnessing steady growth, albeit from a smaller base, as healthcare investments and diabetes screening programs gain momentum in these regions.

Product Type Analysis

The diabetes care devices market is segmented by product type into blood glucose monitoring devices, insulin delivery devices, continuous glucose monitoring (CGM) systems, lancets, a

The global home diabetes care device market is experiencing robust growth, driven by rising prevalence of diabetes, increasing geriatric population, and a shift towards convenient home-based monitoring and treatment. The market, encompassing devices like blood glucose meters, test strips, insulin syringes, insulin pumps, and related supplies, is segmented by application (retail pharmacies, online pharmacies, others) and device type. While precise market sizing requires proprietary data, a reasonable estimate based on industry reports places the 2025 market value around $50 billion, with a Compound Annual Growth Rate (CAGR) of approximately 7% projected through 2033. This growth is fueled by technological advancements resulting in smaller, more user-friendly devices, the integration of smart technology for improved data management and remote patient monitoring, and increased affordability through insurance coverage and generic options. However, the market faces constraints including the high cost of certain advanced devices like insulin pumps, potential device malfunction, and the need for ongoing user education and training. The market's regional distribution reflects global diabetes prevalence patterns. North America and Europe currently dominate market share due to high diabetes rates and advanced healthcare infrastructure. However, rapidly growing economies in Asia Pacific, particularly China and India, are projected to witness significant market expansion in the coming years, driven by increasing awareness, improved healthcare access, and rising disposable incomes. Key players such as Roche, Medtronic, Johnson & Johnson, Abbott, and others, are investing heavily in research and development, focusing on continuous glucose monitoring (CGM) systems and the development of closed-loop insulin delivery systems to maintain a competitive edge and address unmet needs within the market. Competition is fierce, prompting innovation and price adjustments which further contribute to market growth and accessibility.

Diabetes Management Devices Market Outlook

The global diabetes management devices market size was valued at approximately USD 26.5 billion in 2023 and is projected to reach around USD 49.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This growth can be attributed to the increasing prevalence of diabetes, coupled with the rising demand for advanced medical technologies to monitor and manage this chronic condition effectively. The global upsurge in diabetic cases, driven by lifestyle changes, aging populations, and genetic predispositions, forms a significant growth factor. Furthermore, the growing awareness regarding self-monitoring of blood glucose and the potential of technology-driven interventions in diabetes care are expected to propel the market forward over the forecast period.

One of the primary growth drivers for the diabetes management devices market is the rising incidence of diabetes worldwide. Sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates have contributed significantly to the growing diabetic population. The World Health Organization (WHO) estimates that by 2030, diabetes will be the seventh leading cause of death. As the prevalence of diabetes rises, the demand for effective management solutions also increases, creating a robust market for diabetes management devices. Innovations in technology, such as continuous glucose monitoring and closed-loop insulin delivery systems, have transformed diabetes management, offering patients more precise control over their blood glucose levels and improving overall quality of life.

Technological advancements in diabetes management devices have led to the development of more sophisticated and user-friendly devices, further driving market growth. The integration of artificial intelligence (AI) and cloud-based solutions has enabled real-time data tracking and personalized treatment plans, enhancing patient engagement and compliance. Moreover, the proliferation of smartphone applications and wearable technologies has made it easier for patients to monitor their glucose levels and insulin administration remotely. These advancements not only improve patient outcomes but also reduce healthcare costs by minimizing complications associated with poor diabetes management, thus boosting the market for diabetes management devices.

Public health initiatives and government support play a crucial role in the expansion of the diabetes management devices market. Many countries have implemented national diabetes prevention and control programs aimed at raising awareness, promoting early diagnosis, and providing access to affordable diabetes care. For instance, the U.S. government's National Diabetes Prevention Program emphasizes lifestyle changes and routine screenings to prevent or delay the onset of type 2 diabetes. Such initiatives increase the adoption of diabetes management devices as part of comprehensive diabetes care strategies. Additionally, favorable reimbursement policies and coverage for diabetes management devices encourage patients to utilize these technologies, further driving market growth.

From a regional perspective, North America currently dominates the diabetes management devices market, owing to its high diabetes prevalence, advanced healthcare infrastructure, and strong presence of key market players. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by a rising diabetic population, increasing healthcare expenditure, and growing awareness about diabetes management. Emerging markets such as India and China present significant opportunities for market expansion due to their large patient populations and improving access to healthcare services. Moreover, the Middle East and Africa region also demonstrate potential for growth, supported by efforts to improve healthcare systems and address the rising burden of diabetes.

The market for Pet Diabetes Care Devices Sales is also witnessing a notable surge, as awareness about diabetes in pets increases among pet owners. With advancements in veterinary medicine, there is a growing emphasis on the health and wellness of pets, including the management of chronic conditions like diabetes. Pet diabetes care devices, such as glucose monitors and insulin delivery systems, are becoming more sophisticated, mirroring the technological progress seen in human diabetes care. This segment is driven by the rising incidence of diabetes in pets, particularly in cats and dogs, which is often linked

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by rising diabetes prevalence, technological advancements in continuous glucose monitoring (CGM) systems, and increasing demand for convenient and effective diabetes management solutions. The market, valued at approximately $25.16 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors. Firstly, the aging population and increasing sedentary lifestyles contribute significantly to the surge in diabetes cases, creating a larger patient base requiring these devices. Secondly, the continuous innovation in CGM technology, offering real-time glucose monitoring and improved accuracy, is transforming diabetes management. These advancements are driving adoption rates and market expansion. Thirdly, the growing awareness of the importance of proactive diabetes management and self-care is influencing individual choices regarding devices and treatment strategies. While the market demonstrates substantial growth potential, certain factors could restrain its expansion. These include high device costs, particularly for advanced technologies like insulin pumps and CGM systems, which may limit accessibility for some patients. Furthermore, reimbursement policies and insurance coverage can impact market penetration, particularly in regions with limited healthcare access. The market is segmented into self-monitoring blood glucose (SMBG) devices (including glucometers, test strips, and lancets), continuous glucose monitoring (CGM) devices, and insulin delivery devices (such as insulin pumps, syringes, pens, and jet injectors). Competitive landscape analysis reveals key players such as Abbott, Dexcom, Medtronic, and Novo Nordisk, each contributing significantly to market share across various device categories. The North American region, specifically the United States, is expected to maintain a dominant market share owing to its advanced healthcare infrastructure, high diabetes prevalence, and strong regulatory support for innovative medical technologies. The future of the US diabetes devices market appears bright, with continued growth anticipated across various segments, driven by technological advancements, increasing awareness, and a growing patient population. However, addressing affordability and accessibility concerns remains crucial for ensuring market expansion and improved patient outcomes. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The global Diabetes Care Devices market, valued at approximately $XX million in 2025, is projected to experience robust growth, driven by rising diabetes prevalence globally, an aging population, and increasing adoption of advanced technologies like continuous glucose monitoring (CGM). The market's Compound Annual Growth Rate (CAGR) of 5.10% from 2025 to 2033 indicates a significant expansion, with substantial opportunities across various segments. Self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, continue to dominate the market due to their widespread accessibility and affordability. However, the CGM segment is witnessing exponential growth, fueled by its enhanced accuracy, convenience, and ability to provide real-time glucose data, leading to improved diabetes management. The increasing demand for insulin delivery devices, such as insulin pumps, syringes, pens, and jet injectors, also contributes significantly to market expansion. Technological advancements, including the development of integrated devices and improved sensor technologies, are further propelling market growth. The market is geographically diverse, with North America and Europe currently holding the largest market share due to high diabetes prevalence and developed healthcare infrastructure. However, Asia Pacific is emerging as a high-growth region, driven by rising disposable incomes and increasing healthcare awareness. Market restraints include the high cost of advanced devices, particularly CGMs and insulin pumps, which can limit accessibility in low- and middle-income countries. Furthermore, the need for regular calibration and potential inaccuracies associated with some devices present challenges. Despite these restraints, the continuous development of more affordable and user-friendly devices, coupled with supportive government initiatives and rising awareness campaigns, are expected to mitigate these challenges and drive market expansion throughout the forecast period. Key players in the market, including Abbott, Roche, Dexcom, Medtronic, and Novo Nordisk, are heavily invested in research and development, further fueling innovation and market competition. This competitive landscape will continue to shape the market dynamics, leading to advancements in technology and more accessible and affordable diabetes care solutions. Recent developments include: March 2023: Abbott announced that the U.S. Food and Drug Administration cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Notable trends are: The continuous glucose monitoring segment is expected to witness a healthy growth rate over the forecast period.

The North America digital diabetes management market, valued at $27.52 billion in 2025, is projected to experience robust growth, driven by several key factors. The increasing prevalence of diabetes, particularly type 1 and type 2, across the United States and Canada fuels demand for advanced monitoring and management solutions. Technological advancements in continuous glucose monitoring (CGM) systems, offering real-time data and improved accuracy, are significantly impacting market expansion. Furthermore, the rising adoption of insulin pumps and other automated insulin delivery systems, enhancing glycemic control and reducing the burden of self-management, contribute to market growth. The market is segmented into monitoring devices (including glucometers, test strips, lancets, and CGM sensors) and management devices (insulin pumps, syringes, pens, and jet injectors). While the United States dominates the market due to its larger diabetic population and higher healthcare expenditure, Canada also shows promising growth potential. The market's expansion is further supported by favorable government initiatives promoting diabetes management and technological innovation. However, high costs associated with advanced devices and the need for continuous monitoring can present challenges for market accessibility, particularly for lower-income populations. Competitive forces among leading players like Becton Dickinson, Medtronic, Roche, Abbott, and Dexcom are driving innovation and improving the affordability and accessibility of digital diabetes management solutions. Looking ahead to 2033, the market's compound annual growth rate (CAGR) of 6.21% suggests a substantial increase in market size. This sustained growth is anticipated due to continued technological improvements, an aging population increasing diabetes prevalence, and the increasing focus on remote patient monitoring and telehealth solutions. The integration of digital health technologies with existing diabetes management strategies will further enhance the efficiency and effectiveness of treatment. The continued focus on improving patient outcomes and reducing healthcare costs related to diabetes complications will further drive innovation and adoption within this dynamic market segment. The Rest of North America region, while smaller than the US and Canada, is also expected to contribute to overall market growth based on increasing awareness and adoption of digital technologies. Recent developments include: April 2023: Abbott has announced the clearance of its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system by the U.S. Food and Drug Administration (FDA). This system includes a reader that has been approved as a standalone device. Notably, the glucose sensor used in this system is the smallest, thinnest, and most discreet in the world. Abbott is now focused on expediting the process of getting the FreeStyle Libre 3 system included in Medicare's list of covered systems., March 2022: Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Notable trends are: Monitoring Devices is Having the Highest Market Share in Current Year.

The global diabetes care devices market size was valued at USD 34.19 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 62.65 Billion by 2033, exhibiting a CAGR of 6.61% from 2025-2033. North America currently dominates the market, holding a market share of over 38.6% in 2024. The rising incidences of diabetes, rapid technological advancements, imposition of favorable government initiatives, increasing disposable incomes, integration of big data and analytics, and escalating geriatric population are some of the major factors propelling the market.

IMARC Group provides an analysis of the key trends in each segment of the global diabetes care devices market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on type, distribution channel and end user.

The diabetes care device market size is projected to grow from USD 39.82 billion in 2025 to USD 99.81 billion by 2035, representing a CAGR of 9.62% during the forecast period till 2035

Snapshot img

Digital Diabetes Management Market Size 2025-2029

The digital diabetes management market size is forecast to increase by USD 16.57 billion, at a CAGR of 13.6% between 2024 and 2029.

The market is witnessing significant growth due to the rising global burden of diabetes. The increasing prevalence of diabetes and the need for effective management solutions have created a substantial demand for digital diabetes management systems. Another key driver is the integration of Artificial Intelligence (AI) in wearable medical devices, enabling real-time monitoring and analysis of patient data, thereby improving diabetes management and outcomes.
Companies must navigate these regulatory hurdles while ensuring the highest standards of data security and patient privacy to capitalize on the market opportunities and provide effective digital diabetes management solutions. However, the market faces challenges from stringent regulatory frameworks in digital diabetes management. Regulatory bodies are emphasizing data security and privacy concerns, which can hinder market growth.

What will be the Size of the Digital Diabetes Management Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

The market continues to evolve, offering innovative solutions for effective diabetes care across various sectors. Diabetes education resources, such as glycemic control algorithms and insulin pump therapy, have revolutionized type 1 diabetes management. The use of technology and digital tools to help people with diabetes track and control their disease is referred to as digital diabetes management. This covers gadgets, including glucometers, insulin pumps, continuous glucose monitoring systems, and mobile software. The oversight of the appropriate use of these technological instruments and the provision of thorough testing services for diabetes management are crucial functions of diagnostic centers. 
. For instance, a leading diabetes telehealth platform reported a 30% increase in patient engagement through remote monitoring and artificial pancreas systems. Lifestyle modification programs and predictive diabetes models further support patients in managing their condition effectively. Wearable sensor technology and continuous glucose monitoring contribute to improved glycemic control and prevent diabetes complications. Industry growth in digital diabetes management is expected to reach 15% annually, fueled by the integration of secure data transmission and health data interoperability.

How is this Digital Diabetes Management Industry segmented?

The digital diabetes management industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals
  Home settings
  Diagnostic centers


Type

  Wearable devices
  Hand-held devices


Product

  SMBG meters
  Insulin pumps
  CGM devices
  CGM sensors
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By End-user Insights

The Hospitals segment is estimated to witness significant growth during the forecast period. The hospital segment in the global digital diabetes management market refers to the use of digital tools and technologies for the management and treatment of diabetes within a hospital setting. This segment includes various digital solutions such as mobile applications, online platforms, electronic health records (EHRs), medical devices, and telehealth services that are used by healthcare professionals and patients to manage diabetes. The following are some key aspects of the hospital segment in the digital diabetes management market: Remote patient monitoring: Hospitals use technological instruments to remotely check diabetic patients blood glucose levels. Patients can achieve this by using glucose monitoring devices and sending information to medical personnel. It enables continuous monitoring of blood sugar levels, enabling prompt action and individualized treatment advice.

The home settings segment in the global digital diabetes management market refers to the use of digital technologies and devices for managing diabetes in the comfort of an individuals home. It encompasses various digital solutions that enable patients to monitor their blood glucose levels, track their insulin or medication intake, record their diet and exercise, and communicate with healthcare professionals remotely. Some key components of the home-settings segment in digital diabetes management include the following: Blood glucose monitoring tools: Without the necessity for conventional finger-prick testing, these tools enable p

The North America Pet Diabetes Care Devices market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

The global digital diabetes device market is experiencing robust growth, driven by the increasing prevalence of diabetes worldwide, coupled with advancements in technology leading to more sophisticated and user-friendly devices. The market, estimated at $15 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, reaching an estimated market value of $45 billion by 2033. This expansion is fueled by several key factors. The rising adoption of continuous glucose monitoring (CGM) systems and insulin pumps, offering improved diabetes management and better patient outcomes, is a significant contributor. Furthermore, the increasing availability of mobile health (mHealth) applications, facilitating remote patient monitoring and personalized diabetes care, is accelerating market growth. The convenience and accessibility of these digital solutions are particularly appealing to younger generations and those living with busy lifestyles. Technological innovations, such as the integration of artificial intelligence (AI) and machine learning (ML) in diabetes management platforms, are also contributing to market expansion, allowing for more predictive and proactive interventions. Despite this positive trajectory, the market faces some challenges. High costs associated with digital diabetes devices, particularly CGMs and insulin pumps, can limit accessibility, especially in developing countries. Regulatory hurdles and reimbursement complexities also pose obstacles to market penetration. However, these challenges are likely to be mitigated by increasing awareness of the long-term benefits of proactive diabetes management, coupled with ongoing efforts to improve affordability and expand insurance coverage for these devices. The market segmentation reveals a strong preference for digital diabetes apps and instruments, especially in the hospital and clinic settings, which reflects the importance of clinical support in effective diabetes management. The competitive landscape comprises a mix of established medical device companies and emerging tech players, fostering innovation and expanding the range of available solutions. Geographic distribution reveals significant market potential in North America and Europe, with emerging markets in Asia-Pacific showing promising growth opportunities.